InFlectis BioScience's IFB-088 Shows Promising Therapeutic Potential in ALS Treatment
TL;DR
InFlectis BioScience's IFB-088 offers a competitive edge in ALS treatment by targeting TDP-43 proteinopathy with a broader mechanism than current therapies.
IFB-088 modulates the Unfolded Protein Response to reduce TDP-43 mislocalization and abnormal RNA splicing, enhancing motor neuron survival in ALS models.
InFlectis BioScience's research on IFB-088 brings hope for a better future for ALS patients by addressing a major unmet need in therapy.
Discover how IFB-088, a novel therapy by InFlectis BioScience, improves motor neuron survival and function in ALS models through innovative research.
Found this article helpful?
Share it with your network and spread the knowledge!
InFlectis BioScience has announced the publication of a groundbreaking study in the peer-reviewed journal Life Science Alliance, showcasing the therapeutic potential of IFB-088 in treating amyotrophic lateral sclerosis (ALS). The study, titled 'Sephin1 reduces TDP-43 cytoplasmic mislocalization and improves motor neuron survival in ALS models,' provides preclinical evidence that IFB-088, a modulator of the Unfolded Protein Response (UPR), significantly mitigates the pathological hallmarks of ALS.
The research, conducted in collaboration with leading European academic and clinical institutions, demonstrates that IFB-088 reduces cytoplasmic mislocalization of TDP-43, a feature present in 97% of ALS cases, and decreases abnormal RNA splicing linked to TDP-43 nuclear loss of function. These findings suggest a novel approach to ALS therapy, targeting the cellular stress response to offer broader therapeutic benefits than current treatments focusing on single genes.
Dr. Emmanuelle Abgueguen, the study's lead author, emphasized the significance of IFB-088's mechanism of action, which addresses the root cause of TDP-43 proteinopathy. The study's results, showing improved motor neuron survival and function in various ALS models, including SOD1G93A mice and TDP-43 transgenic zebrafish, underscore the compound's potential as a disease-modifying therapy.
InFlectis BioScience is advancing IFB-088 through clinical development, with a recently completed Phase II trial in bulbar-onset ALS patients. Dr. Pierre Miniou, COO of InFlectis BioScience, highlighted the importance of securing partnerships to finance upcoming Phase 2B clinical trials, crucial for bringing IFB-088 to patients in need. The full study is available via the Life Science Alliance website, marking a significant step forward in the quest for effective ALS treatments.
Curated from Reportable
